Abstract 3621
Background
Capecitabine plus cisplatin (XP) is a standard treatment for metastatic gastric cancer (mGC). Capecitabine activation requires the enzymes uridine-cytidine kinase 2 (UCK2) and orotate phosphoribosyl transferase (OPRT). We previously used mass spectrometry to quantitate UCK2 in tumor samples from 5-FU-treated patients with stage II/III colorectal cancer; UCK2 protein expression > 319 amol/ug of tumor protein was associated with improved survival. Here, we assessed whether these biomarkers would predict survival among mGC patients treated with XP.
Methods
Archived tumor samples from patients with mGC were microdissected and solubilized for mass spectrometric quantitation of 16 protein biomarkers. Kaplan-Meier survival curves were compared using a log-rank test. Multivariate Cox models of survival included clinical covariates and protein biomarkers.
Results
mGC tumor samples from 116 XP-treated patients were analyzed (males: 64%; median age: 55 years). All samples expressed OPRT protein (range: 202 – 1719 amol/ug), and 114 of 116 expressed UCK2 (range: 119 – 933 amol/ug). Patients with UCK2 expression above the pre-defined cutoff of 319 amol/μg (n = 30) had longer time to progression (TTP) (HR: 0.60; p = 0.020) than patients below the cutoff. Results for overall survival (OS) were similar (HR: 0.59; p = 0.015). OPRT protein expression > 790 amol/ug (n = 24) was associated with longer TTP (HR: 0.58; p = 0.019) and longer OS (HR: 0.60; p = 0.029). In multivariate analysis, UCK2 and OPRT remained independent predictors of survival after adjustment for age, gender, ECOG performance status, metastatic sites, and other clinical covariates.
Conclusions
We validated a pre-defined UCK2 expression cutoff and discovered an OPRT cutoff in an XP-treated mGC patient cohort. Patients with tumor expression of UCK2 and OPRT proteins above quantified thresholds survived longer than patients with lower expression. Mass spectrometric quantitation of these common tumor proteins at diagnosis may improve patient selection for XP. Studies to validate these and other chemopredictive biomarkers are ongoing.
Clinical trial identification
Legal entity responsible for the study
NantOmics.
Funding
NantOmics.
Editorial Acknowledgement
Disclosure
D. Yan, E. An, Y. Tian, F. Cecchi, T. Hembrough: Employment: NantOmics. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract